CEACAM5 and cholangiocarcinoma: In line with this finding, ROC curve analysis revealed that serum levels of CEA (AUC: 0.813) were superior to CA19-9 levels (AUC: 0.768) in differentiating between patients with PSC and CCA (Fig. 2e).